TriSalus Life Sciences, Inc. Common Stock
TLSIStock
$4.36−18.88%52W
Market Cap$248.12M
P/E—
Div yield—
Beta0.40
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-40.09%
Price vs S&P 500 (4W)-3.41%
VGM Score44.17
Market Capitalization$248.12M
Earnings Surprise History
Q1 260.03est. -0.16
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.09
4.09
4.09
4.10
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLSITriSalus Life Sciences, Inc. Common Stock | D | C | C | $4.36 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics for difficult-to-treat hepatocellular and pancreatic cancers. The company commercializes PEDD infusion systems through its TriNav platform with SmartValve technology, while advancing the investigational agent nelitolimod (SD-101) to enhance immune response in liver and pancreatic cancer patients.